Kalaris Therapeutics (NASDAQ:KLRS) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Kalaris Therapeutics (NASDAQ:KLRS) from a sell rating to a hold rating in a report published on Sunday.

Other research analysts also recently issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Kalaris Therapeutics in a research report on Monday, December 29th. Chardan Capital assumed coverage on Kalaris Therapeutics in a research note on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 price target on the stock. Finally, Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Kalaris Therapeutics Stock Down 5.5%

Shares of Kalaris Therapeutics stock opened at $8.67 on Friday. Kalaris Therapeutics has a 12-month low of $2.14 and a 12-month high of $12.90. The company has a market capitalization of $162.13 million, a price-to-earnings ratio of -2.30 and a beta of -0.13. The firm’s 50-day moving average price is $9.44 and its two-hundred day moving average price is $7.21.

Insider Buying and Selling at Kalaris Therapeutics

In other news, Director Srinivas Akkaraju acquired 479,847 shares of Kalaris Therapeutics stock in a transaction that occurred on Thursday, December 18th. The shares were acquired at an average price of $10.42 per share, for a total transaction of $5,000,005.74. Following the transaction, the director directly owned 1,979,847 shares of the company’s stock, valued at approximately $20,630,005.74. The trade was a 31.99% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 74.99% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Kalaris Therapeutics during the fourth quarter valued at $34,000. Barclays PLC bought a new position in Kalaris Therapeutics during the 4th quarter worth $51,000. Johnson Financial Group Inc. bought a new position in Kalaris Therapeutics during the 3rd quarter worth $58,000. Keel Point LLC acquired a new position in Kalaris Therapeutics during the 4th quarter worth about $86,000. Finally, XTX Topco Ltd bought a new stake in shares of Kalaris Therapeutics in the 4th quarter valued at about $92,000. Institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.